


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.


Listing of Claims:

1. (original) A compound having the formula I, or a pharmaceutically acceptable salt thereof,



wherein

Y is -NH-R² or a group of formula



R¹ is cycloalkyl or non-substituted alkyl,

R² is cycloalkyl,

R³ is hydrogen, alkyl, halogen, hydroxy, alkoxy or amino,
or R²R³ is an alkylene bridging group,


R^a is hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, amino,
alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido,

R^b is hydrogen, alkyl or halogen,
or R^aR^b is carbonyl,

R⁴ is hydrogen or alkyl,

R⁵ is cycloalkyl, arylalkyl or heterocycle-alkyl,
or NR⁴R⁵ is a heterocycle, which may be substituted, containing only one
heteroatom which is a nitrogen atom or containing two heteroatoms wherein one
is a nitrogen atom and the other is a non-oxidized sulfur atom,

with the proviso that when Y is $-NHR^2$ and R^2R^3 is an alkylene bridging group or when Y is a group of formula



R^1 is a cycloalkyl.

2. (original) A compound according to claim 1 wherein Y is $-NH-R^2$.

3. (original) A compound according to claim 2 wherein

R^1 is C3-7-cycloalkyl or non-substituted alkyl,

R^2 is C3-7-cycloalkyl,

R^3 is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino,

or R^2R^3 is a C2-4-alkylene bridging group,

R^4 is hydrogen or C1-4-alkyl,

R^5 is C3-7-cycloalkyl, arylalkyl or heterocycle-alkyl,

or NR^4R^5 is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom.

4. (Currently amended) A compound according to claim 2 or 3 wherein R^1 is C3-4-alkyl or C3-5-cycloalkyl, preferably cyclopropyl, isopropyl, cyclobutyl, cyclopentyl, 2-methyl-cyclopropyl or cyclopropylmethyl.

5. (Currently amended) A compound according to ~~any of claims 2 to 4~~ claim 2 wherein

R^2 is a C3-4-non-substituted cycloalkyl, or a cycloalkyl substituted by a C1-6-alkyl or an aryl, preferably cyclopropyl or cyclobutyl,

and/or R^3 is hydrogen, methyl, ethyl, a Cl atom, a F atom, a Br atom, amino or methoxy,


or R^2R^3 is an alkylene bridging group selected from ethylene, propylene and butylene.

6. (Currently amended) A compound according to ~~any of claims 2 to 5~~ claim 2 wherein

R^4 is hydrogen or C1-4-alkyl, preferably hydrogen or methyl, and/or R^5 is 2-(2-thienyl)ethyl, 2-furylmethyl, 2-thienylmethyl, 4-pyridinylmethyl, benzyl, 2-(methylsulfanyl)benzyl, 2,6-difluorobenzyl, 2-fluorobenzyl, 2-nitrobenzyl, 3,5-bis(trifluoromethyl)benzyl, 3,5-difluorobenzyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, or 2,2-diphenylethyl, or NR^4R^5 is 1,3-thiazolidin-3-yl, 1-azepanyl, 1-azocanyl, 3,5-dimethyl-1-piperidinyl, 4-(2-methoxyphenyl)-1-piperidinyl, 4-(hydroxy(diphenyl)methyl)-1-piperidinyl, 4-(trifluoromethyl)-1-piperidinyl, 4,4-difluoro-1-piperidinyl, 4,4-dimethyl-1-piperidinyl, 4-carbamoyl-1-piperidinyl, 4-benzyl-1-piperidinyl, 4-carboxy-1-piperidinyl, 4-cyano-4-phenyl-1-piperidinyl, 4-ethoxycarbonyl-1-piperidinyl, 4-ethyl-1-piperidinyl, 4-ethyl-4-methyl-1-piperidinyl, 4-hydroxy-1-piperidinyl, 4-hydroxy-4-phenyl-1-piperidinyl, 4-hydroxymethyl-1-piperidinyl, 4-methyl-1-piperidinyl, 4-methylene-1-piperidinyl, 4-oxo-1-piperidinyl, 3,6-dihydro-1(2H)-pyridinyl, 3-azabicyclo[3.2.1]oct-3-yl, 4-thiomorpholinyl, 2-one-1-azepanyl, 3,4-dihydro-2(1H)-isoquinolinyl, 1,4-dioxa-8-azaspiro[4.5]dec-8-yl, 1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, octahydro-2(1H)-isoquinolinyl or 8-azaspiro[4.5]dec-8-yl.

7. (original) A compound selected from 6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; 6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine and 4-azepan-1-yl-2-cyclopropyl-6,7,8,9-tetrahydro-pyrimido[4,5-b]azepine, or pharmaceutically acceptable salts thereof.

8. (original) A compound according to claim 1 wherein Y is a group of formula



9. (original) A compound according to claim 8 wherein NR⁴R⁵ is a 5- to 9-membered heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom, preferably 1-azepanyl.

10. (original) A compound according to claim 9 wherein

R¹ is C3-7-cycloalkyl,

R³ is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino,

R^a is hydrogen, C1-4-alkyl, C2-6-alkenyl, C2-6-alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido,

R^b is hydrogen, C1-4-alkyl or halogen,

or R^aR^b is carbonyl.

11. (Currently amended) A compound according to ~~any of claims 8 to 10~~ claim 10 wherein R¹ is C3-4-cycloalkyl, preferably cyclopropyl.

12. (Currently amended) A compound according to ~~any of claims 8 to 11~~ claim 10 wherein R³ is hydrogen or C1-4-alkyl, preferably hydrogen or methyl.

13. (Currently amended) A compound according to ~~any of claims 8 to 12~~ claim 10 wherein


R^a is hydrogen, methyl, hydroxy, methoxy, methylsulfonyloxy, a Br atom, a F atom or cyano, preferably, hydrogen, methyl, hydroxy or a F atom,
and/or R^b is hydrogen or methyl, preferably hydrogen,

or R^aR^b is carbonyl.

14. (original) A compound selected from 1-(6-azetidin-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl)azepane and 1-[2-cyclopropyl-5-methyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane, or pharmaceutically acceptable salts thereof.
15. (Currently amended) A compound according to ~~any preceding claims~~ claim 1 as a pure enantiomer.
16. (Currently amended) A pharmaceutical composition comprising an effective amount of a compound according to ~~any preceding claim 1~~ in combination with a pharmaceutically acceptable diluent or carrier.
17. (original) A pharmaceutical composition according to claim 16 for administration by inhalation.
18. (Currently amended) A compound according to ~~any of claims 1-15~~ claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament.
19. (Currently amended) The use of a compound according to ~~any of claims 1-15~~ claim 1 for the manufacture of a medicament for the treatment of respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treatment of symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma.
20. (Currently amended) A method for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma comprising administering at least


one compound according to ~~claims 1-15~~ claim 1 or a pharmaceutically acceptable salt thereof to a patient.

21. (original) A compound of formula II, or a pharmaceutically acceptable salt thereof,



wherein

Y is -NH-R² or a group of formula



R¹ is cycloalkyl or non-substituted alkyl,

R² is cycloalkyl,


R³ is hydrogen, alkyl, halogen, alkoxy or hydroxy,

R^a is hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido,

R^b is hydrogen, alkyl or halogen,


or R^aR^b is carbonyl.

22. (original) A compound of formula VI, or a pharmaceutically acceptable salt thereof,




wherein R¹ is C3-5-cycloalkyl or non-substituted alkyl, and R³ is alkoxy.

23. (original) A compound of formula X, or a pharmaceutically acceptable salt thereof,



wherein n is 1-6, and R¹ is cycloalkyl.

24. (original) A compound of formula XII, or a pharmaceutically acceptable salt thereof,



wherein R¹ is cycloalkyl.

25. (original) A compound selected from the group consisting of 6-chloro-N,2-dicyclopethyl-5-fluoro-4-pyrimidinamine; 6-chloro-N,2-dicyclopethyl-4-pyrimidinamine; 6-chloro-N,2-dicyclopethyl-5-methyl-4-pyrimidinamine; 5,6-dichloro-N,2-dicyclopethyl-4-pyrimidinamine; 6-chloro-N,2-dicyclopethyl-5-methoxy-4-pyrimidinamine; 6-chloro-N,2-dicyclopethyl-5-ethyl-4-pyrimidinamine; N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine and its enantiomers; 6-chloro-N-cyclopropyl-5-methyl-2-(2-trans-methylcyclopropyl)-4-pyrimidinamine; 6-chloro-N-cyclopropyl-5-methyl-2-(2-cis-methylcyclopropyl)-4-pyrimidinamine; N-[6-chloro-2-(cyclopropylmethyl)-5-methyl-4-pyrimidinyl]-N-cyclopropylamine; 6-chloro-2-cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine; 6-chloro-N,2-dicyclopethyl-5-nitro-4-pyrimidinamine; 6-chloro-N-cyclobutyl-2-cyclopropyl-5-methyl-4-pyrimidinamine; 6-chloro-N-cyclopropyl-2-isopropyl-5-methyl-4-pyrimidinamine; 6-chloro-2-cyclopentyl-N-cyclopropyl-5-methyl-4-pyrimidinamine; 6-chloro-2-cyclopropyl-5-methyl-N-(2-methylcyclopropyl)-4-pyrimidinamine; 6-chloro-2-cyclopropyl-5-methyl-N-(1-methylcyclopropyl)-4-

pyrimidinamine; 6-chloro-2-cyclopropyl-5-methyl-N-(2-phenylcyclopropyl)-4-pyrimidinamine; 4-(1-azetidinyl)-6-chloro-2-cyclopropyl-5-methylpyrimidine; 4-(1-azetidinyl)-6-chloro-2-cyclopropylpyrimidine; 4-chloro-2-cyclopropyl-5-methyl-6-(3-methyl-1-azetidinyl)pyrimidine; 4-chloro-2-cyclopropyl-6-(3-methyl-1-azetidinyl)pyrimidine; 4-chloro-2-cyclopropyl-6-(3,3-dimethyl-1-azetidinyl)-5-methylpyrimidine; 1-(6-chloro-2-cyclopropyl-5-methyl-4-pyrimidinyl)-3-azetidinol; 4-chloro-2-cyclopropyl-6-(3-fluoro-1-azetidinyl)-5-methylpyrimidine; 4-chloro-2-cyclopropyl-6-(3-fluoro-1-azetidinyl)pyrimidine; 4-chloro-2-cyclopropyl-6-(3-methoxy-1-azetidinyl)-5-methylpyrimidine; 2-methylcyclopropanecarboximidamide; 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol; 5-chloro-2-cyclopropyl-4,6-pyrimidinediol; 2-cyclopropyl-5-methoxy-4,6-pyrimidinediol; 2-cyclopropyl-5-ethyl-4,6-pyrimidinediol; 2-(2-methylcyclopropyl)-4,6-pyrimidinediol; 5-methyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediol; 2-(cyclopropylmethyl)-5-methyl-4,6-pyrimidinediol; 2-cyclobutyl-5-methyl-4,6-pyrimidinediol; 2-isopropyl-5-methyl-4,6-pyrimidinediol; 2-cyclopentyl-5-methyl-4,6-pyrimidinediol; [3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-propyl]-carbamic acid tert-butyl ester; [4-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-butyl]-carbamic acid tert-butyl ester; 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine; 4,5,6-trichloro-2-cyclopropylpyrimidine; 4,6-dichloro-2-cyclopropyl-5-pyrimidinyl methyl ether; 4,6-dichloro-2-cyclopropyl-5-ethylpyrimidine; 4,6-dichloro-2-(2-methylcyclopropyl)pyrimidine; 4,6-dichloro-5-methyl-2-(2-methylcyclopropyl)pyrimidine; 4,6-dichloro-2-(cyclopropylmethyl)-5-methylpyrimidine; 4,6-dichloro-2-cyclobutyl-5-methylpyrimidine; 4,6-dichloro-2-isopropyl-5-methylpyrimidine; 4,6-dichloro-2-cyclopentyl-5-methylpyrimidine; 6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine; 4-chloro-2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine; 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrido[2,3-d]pyrimidine; 4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]azepine; 2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ol; 3-fluoroazetidine hydrochloride and 1-benzhydryl-3-fluoroazetidine.

26. (New) A pharmaceutical composition comprising an effective amount of a compound according to claim 7 in combination with a pharmaceutically acceptable diluent or carrier.
27. (New) A pharmaceutical composition comprising an effective amount of a compound according to claim 14 in combination with a pharmaceutically acceptable diluent or carrier.
28. (New) A compound according to claim 7 as a pure enantiomer.
29. (New) A compound according to claim 14 as a pure enantiomer.
30. (New) A pharmaceutical composition according to claim 26 for administration by inhalation.
31. (New) A pharmaceutical composition according to claim 27 for administration by inhalation.
32. (New) A method for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma comprising administering at least one compound according to claim 7 or a pharmaceutically acceptable salt thereof to a patient.
33. (New) A method for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma comprising administering at least one compound according to claim 14 or a pharmaceutically acceptable salt thereof to a patient.